References
- Jee Y. WHO international health regulations emergency committee for the COVID-19 outbreak. Epidemiol Health. 2020;42:e2020013. doi:https://doi.org/10.4178/epih.e2020013.
- Giorgi Rossi P, Marino M, Formisano D, Venturelli F, Vicentini M, Grilli R, The Reggio Emilia COVID-19 Working Group. Characteristics and outcomes of a cohort of COVID-19 patients in the Province of Reggio Emilia, Italy. PLoS One. 2020;15(8):e0238281. doi:https://doi.org/10.1371/journal.pone.0238281.
- WHO. COVID-19 weekly epidemiological update, edition 58, 21 September 2021. 2021.
- Cascetta E, Henke I, Di Francesco L. The effects of air pollution, sea exposure and altitude on COVID-19 hospitalization rates in Italy. IJERPH. 2021;18(2):452. doi:https://doi.org/10.3390/ijerph18020452.
- Siavashpour Z, Taghizadeh-Hesary F, Rakhsha A. Recommendations on management of locally advanced rectal cancer during the COVID-19 pandemic: an Iranian Consensus. J Gastrointest Canc. 2020;51(3):800–805. doi:https://doi.org/10.1007/s12029-020-00454-4.
- Rakhsha A, Azghandi S, Taghizadeh-Hesary F. COVID-19 pandemic and patients with cancer: the protocol of a clinical oncology center in Tehran, Iran. Rep Pract Oncol Radiother. 2020;25(5):765–767. doi:https://doi.org/10.1016/j.rpor.2020.07.001.
- Rüthrich MM, Giessen-Jung C, Borgmann S, Classen A, Dolff S, Grüner B, on behalf of the LEOSS Study Group, et al. COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry. Ann Hematol. 2021;100(2):383–393. doi:https://doi.org/10.1007/s00277-020-04328-4.
- Riera R, Bagattini ÂM, Pacheco RL, Pachito DV, Roitberg F, Ilbawi A. Delays and disruptions in cancer health care due to COVID-19 pandemic: systematic review. JCO Glob Oncol. 2021;7:311–323. doi:https://doi.org/10.1200/go.20.00639.
- Soroosh D, Javadinia SA. The COVID-19 outbreak and oncology centers in Iran. Int J Cancer Manag. 2020;13(6):e103283. doi:https://doi.org/10.5812/ijcm.103283.
- Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov. 2020;10(7):935–941. doi:https://doi.org/10.1158/2159-8290.CD-20-0516.
- Taghizadeh-Hesary F, Porouhan P, Soroosh D, PeyroShabany B, Shahidsales S, Keykhosravi B, et al. COVID-19 in cancer and non-cancer patients. Int J Cancer Manag. 2021;14(4):e110907. doi:https://doi.org/10.5812/ijcm.110907.
- Shahidsales S, Aledavood SA, Joudi M, Molaie F, Esmaily H, Javadinia SA. COVID-19 in cancer patients may be presented by atypical symptoms and higher mortality rate, a case-controlled study from Iran. Cancer Rep (Hoboken). 2021;4(5):e1378. doi:https://doi.org/10.1002/cnr2.1378.
- Kong X, Qi Y, Huang J, Zhao Y, Zhan Y, Qin X, et al. Epidemiological and clinical characteristics of patients with COVID-19 who have cancer: a systematic review and meta-analysis of global data. Cancer Lett. 2021;508:30–46. doi:https://doi.org/10.1016/j.canlet.2021.02.012.
- Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Clinical characteristics and outcomes of cancer patients with COVID-19. J Med Virol. 2020;92(10):2067–2073. doi:https://doi.org/10.1002/jmv.25972.
- Barlesi F, Foulon S, Bayle A, Gachot B, Pommeret F, Willekens C, et al. Abstract CT403: Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments. AACR; 2020. doi:https://doi.org/10.1158/1538-7445.AM2020-CT403.
- Javadinia SA, Ariamanesh M, Nabavifard M, Porouhan P, PeyroShabany B, Fazilat-Panah D, et al. Multicenter study of antibody seroprevalence against COVID-19 in patients presenting to Iranian cancer centers after one year of the COVID-19 pandemic. Cancer Invest. 2022;40(2):115–119. doi:https://doi.org/10.1080/07357907.2021.1995742.
- Ariamanesh M, Porouhan P, PeyroShabany B, Fazilat-Panah D, Dehghani M, Nabavifard M, et al. Immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with malignancy. Cancer Invest. 2022;40(1):26–29. doi:https://doi.org/10.1080/07357907.2021.1992420.
- Joudi M, Moradi Binabaj M, Porouhan P, PeyroShabany B, Tabasi M, Fazilat-Panah D, et al. A Cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer; does trastuzumab interfere with the outcome? Front Endocrinol (Lausanne). 2022;13:798975. doi:https://doi.org/10.3389/fendo.2022.798975.
- Javadinia SA, Alizadeh K, Mojadadi MS, Nikbakht F, Dashti F, Joudi M, et al. COVID-19 vaccination in patients with malignancy; a systematic review and meta-analysis of the efficacy and safety. Front Endocrinol. 2022; 13. doi:https://doi.org/10.3389/fendo.2022.860238.
- Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907–1918. doi:https://doi.org/10.1016/S0140-6736(20)31187-9.
- Fillmore NR, La J, Szalat RE, Tuck DP, Nguyen V, Yildirim C, et al. Prevalence and outcome of COVID-19 infection in cancer patients: a national Veterans Affairs study. JNCI: J Natl Cancer Inst. 2021;113(6):691–698. doi:https://doi.org/10.1093/jnci/djaa159.
- Miyashita H, Mikami T, Chopra N, Yamada T, Chernyavsky S, Rizk D, et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol. 2020;31(8):1088–1089. doi:https://doi.org/10.1016/j.annonc.2020.04.006.
- Nadkarni AR, Vijayakumaran SC, Gupta S, Divatia JV. Mortality in cancer patients with COVID-19 who are admitted to an ICU or who have severe COVID-19: a systematic review and meta-analysis. JCO Glob Oncol. 2021;7:1286–1305. doi:https://doi.org/10.1200/GO.21.00072.
- Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99. doi:https://doi.org/10.3322/caac.21388.
- Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3(1):17–18. doi:https://doi.org/10.1186/1751-0473-3-17.
- Liu D, Ma Z, Yang J, Zhao M, Ao H, Zheng X, et al. Prevalence and prognosis significance of cardiovascular disease in cancer patients: a population-based study. Aging (Albany NY). 2019;11(18):7948–7960. doi:https://doi.org/10.18632/aging.102301.
- Yigenoglu TN, Ata N, Altuntas F, Bascı S, Dal MS, Korkmaz S, et al. The outcome of COVID-19 in patients with hematological malignancy. J Med Virol. 2021;93(2):1099–1104. doi:https://doi.org/10.1002/jmv.26404.
- Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881–2892. doi:https://doi.org/10.1182/blood.2020008824.
- Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer. JAMA Oncol. 2022;8(1):69. doi:https://doi.org/10.1001/jamaoncol.2021.5148.
- Li Y. T-cell immune suppression in patients with hematologic malignancies: clinical implications. Int J Hematol Oncol. 2014;3(4):289–297. doi:https://doi.org/10.2217/ijh.14.23.
- Patel SA, Rameshwar P. Stem cell transplantation for hematological malignancies: prospects for personalized medicine and co-therapy with mesenchymal stem cells. Curr Pharmacogenomics Person Med. 2011;9(3):229–239. doi:https://doi.org/10.2174/187569211796957548.
- Rome RB, Luminais HH, Bourgeois DA, Blais CM. The role of palliative care at the end of life. Ochsner J. 2011;11(4):348–352.
- Corso CR, Mulinari Turin de Oliveira N, Maria-Ferreira D. Susceptibility to SARS-CoV-2 infection in patients undergoing chemotherapy and radiation therapy. J Infect Public Health. 2021;14(6):766–771. doi:https://doi.org/10.1016/j.jiph.2021.03.008.
- Garassino MC, Whisenant JG, Huang L-C, Trama A, Torri V, Agustoni F, TERAVOLT investigators, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21(7):914–922. doi:https://doi.org/10.1016/S1470-2045(20)30314-4.
- Tang M, Daniels B, Aslam M, Schaffer A, Pearson S-A. Changes in systemic cancer therapy in Australia during the COVID-19 pandemic: a population-based study. Lancet Reg Health West Pac. 2021;14:100226. doi:https://doi.org/10.1016/j.lanwpc.2021.100226.
- Akbari H, Taghizadeh-Hesary F, Bahadori M. Mitochondria determine response to anti-programmed cell death protein 1 (Anti-PD-1) immunotherapy: an evidence-based hypothesis. Mitochondrion. 2022;62:151–158. S1567-7249 (21) 00168-9. doi:https://doi.org/10.1016/j.mito.2021.12.001.
- Pezeshki PS, Rezaei N. Immune checkpoint inhibition in COVID-19: risks and benefits. Expert Opin Biol Ther. 2021;21(9):1173–1179. doi:https://doi.org/10.1080/14712598.2021.1887131.
- Jarahzadeh MH, Asadian F, Farbod M, Meibodi B, Abbasi H, Jafari M, et al. Cancer and coronavirus disease (COVID-19): comorbidity, mechanical ventilation, and death risk. J Gastrointest Canc. 2021;52(1):80–85. doi:https://doi.org/10.1007/s12029-020-00529-2.
- Chai C, Feng X, Lu M, Li S, Chen K, Wang H, et al. One‐year mortality and consequences of COVID‐19 in cancer patients: a cohort study. IUBMB Life. 2021;73(10):1244–1256. doi:https://doi.org/10.1002/iub.2536.
- Flanigan PM, Jahangiri A, Kuang R, Truong A, Choi S, Chou A, et al. Improved survival with decreased wait time to surgery in glioblastoma patients presenting with seizure. Neurosurgery. 2017;81(5):824–833. doi:https://doi.org/10.1093/neuros/nyx084.
- Russell B, Moss CL, Palmer K, Sylva R, D’souza A, Wylie H, et al. COVID-19 risk factors for cancer patients: a first report with comparator data from COVID-19 negative cancer patients. Cancers. 2021;13(10):2479. doi:https://doi.org/10.3390/cancers13102479.
- Johannesen TB, Smeland S, Aaserud S, Buanes EA, Skog A, Ursin G, et al. COVID-19 in cancer patients, risk factors for disease and adverse outcome, a population-based study from Norway. Front Oncol. 2021;11(1010):652535. doi:https://doi.org/10.3389/fonc.2021.652535.